Drug Company Success Depends on New Development Paradigms, According to Tufts Center for the Study of Drug Development
January 07, 2014 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jan 7, 2014) - While many drug developers continue to improve clinical trial operational efficiency to increase the pace of new product introductions, their medium- and...
Biotech Products in Big Pharma Clinical Pipelines Have Grown Dramatically According to the Tufts Center for the Study of Drug Development
November 14, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Nov 14, 2013) - The pharmaceutical industry, especially Big Pharma, has dramatically shifted its R&D focus from its historical concentration on small molecule drugs...
Drug Sponsors and Their External Service Partners Say Adjusting Relationship Models Offers a Path to Greater Performance and Efficiency, According to Tufts Center for the Study of Drug Development
October 08, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Oct 8, 2013) - While drug sponsor use of strategic relationships with contract service providers has increased dramatically during the past five years, improvements in...
Clinical Study Failures Vary Widely by Phase of Study and Therapeutic Class, According to the Tufts Center for the Study of Drug Development
September 10, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Sep 10, 2013) - While lack of commercial viability is the leading cause of Phase I failures for new drug candidates, efficacy issues dominate as the reason for Phase II...
Drug Industry Leaders See Collaboration as Key to Greater Productivity, According to Tufts Center for the Study of Drug Development
August 13, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Aug 13, 2013) - Responding to a widely shared need to improve the probability of R&D success, leaders from the research-based drug industry, recently convened by...
Number of Annual New Drug Approvals to Treat Neglected Diseases Has Nearly Doubled Between the Early-2000s and 2009-12, According to the Tufts Center for the Study of Drug Development
July 11, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Jul 11, 2013) - The annual number of new drug approvals worldwide to treat neglected diseases has nearly doubled in recent years, with HIV/AIDS and malaria drugs...
Clinical Success Rates for New Cancer Drugs Doubled From the Mid-1990s to Early-2000s, According to the Tufts Center for the Study of Drug Development
May 07, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - May 7, 2013) - Clinical success rates for new cancer drugs doubled between the mid-1990s to the early 2000s, while the number of new cancer drugs entering clinical...
New Protocol Design Approaches Will Improve Clinical Trial Performance and Efficiency, According to Tufts Center for the Study of Drug Development
April 09, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwired - Apr 9, 2013) - Growing protocol complexity -- responsible for longer clinical study times, greater difficulty in recruiting volunteers, and rising drug development costs...
Companion Diagnostics, Key to Development of Personalized Medicines, Face Hurdles, According to Tufts Center for the Study of Drug Development
January 24, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jan 24, 2013) - Companion diagnostics, which are central to the creation of personalized medicines, have captured the interest of many drug companies, but face a number of...
New Research From Tufts Center for the Study of Drug Development Characterizes Effectiveness and Variability of Patient Recruitment and Retention Practices
January 15, 2013 09:00 ET
|
Tufts Center for the Study of Drug Development
BOSTON, MA--(Marketwire - Jan 15, 2013) - While nine out of 10 clinical trials worldwide meet their patient enrollment goals, reaching those targets typically means that drug developers need to...